Condition
AATD
Total Trials
6
Recruiting
1
Active
1
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
Termination Rate
16.7%
1 terminated out of 6 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
75% success
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Completed3
Recruiting1
Withdrawn1
Terminated1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT06677307Phase 1Terminated
A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110
NCT01851642Recruiting
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
NCT06622668Phase 1Withdrawn
NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease
NCT01810458Completed
Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)
NCT03815396Phase 1Completed
Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency
NCT01832220Completed
Genomic Research in Alpha-1 Antitrypsin Deficiency
Showing all 6 trials